Friday, July 31, 2026
Science

By making key signaling molecules called β-arrestins into druggable targets, scientists crack long-standing challenge

To function normally, nearly every cell in the human body relies on G-protein-coupled receptors (GPCRs) to receive and send signals. That's why GPCRs are targeted by roughly one-third of all FDA-approved drugs.

By making key signaling molecules called β-arrestins into druggable targets, scientists crack long-standing challenge
Image: Phys.org
To function normally, nearly every cell in the human body relies on G-protein-coupled receptors (GPCRs) to receive and send signals. That's why GPCRs are targeted by roughly one-third of all FDA-approved drugs.

Originally published at Phys.org

The Morning Briefing

Subscribe to our Newsletter

Be the first to receive the latest news, market analysis and updates — delivered straight to your inbox.